New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs KPV

Pancragen vs KPV

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Immune SupportRecovery & Repair
KPV
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
Half-Life
Short (minutes); sustained gene-regulatory effects
Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
Admin Route
SubQ, Oral
Oral, SubQ, Topical
Research
Typical Dose
10 mg per day
500 mcg – 1 mg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Reduces intestinal inflammation (IBD, Crohn's, colitis)
  • Promotes gut mucosal healing and barrier integrity
  • Accelerates wound healing topically
  • Suppresses systemic inflammatory cytokines
  • Antimicrobial properties against pathogens
  • Reduces neuroinflammation when administered systemically
  • May improve symptoms of inflammatory skin conditions
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally very well tolerated
  • Mild injection site reactions (SC)
  • Rare: transient flushing
Stacks With